Royalty Pharma to present at upcoming investor conferences

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May:

GlobeNewsWire • 18 hours ago

Royalty Pharma plc (RPRX) Q1 2026 Earnings Call Transcript

Royalty Pharma plc (RPRX) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 6, 2026

Royalty Pharma reports first quarter 2026 results

Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13% Net cash provided by operating activities of $718 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,325 million to $3,450 million NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts. “Royalty Pharma has delivered a strong start to 2026 across multiple dimensions.

GlobeNewsWire • May 6, 2026

Royalty Pharma (RPRX) Q1 Earnings and Revenues Surpass Estimates

Royalty Pharma (RPRX) came out with quarterly earnings of $1.3 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $1.06 per share a year ago.

Zacks Investment Research • May 6, 2026

Royalty Pharma PLC (RPRX) Hit a 52 Week High, Can the Run Continue?

Royalty Pharma (RPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Investment Research • May 6, 2026

RPRX vs. AMGN: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Royalty Pharma (RPRX) and Amgen (AMGN). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research • May 6, 2026

An 8-Hour AI Result Is Testing Pharma's $10 Billion Royalty Market

The drug royalty business thrives on a bet that an approved biologic will keep printing money along a predictable schedule. Patent expires here, biosimilar enters there, revenue declines at roughly this rate.

Forbes • May 1, 2026

Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Apr 29, 2026

Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the launch of the Royalty Pharma Translational Prize, which recognizes exceptional achievements in translational medicine. The Prize will honor scientific breakthroughs that bridge the gap between fundamental discovery and the development of new medicines that improve and extend patients' lives. It will include a $1 million award distributed among one or more established scientists whose work has translated unique scientific insights into medicines with significant impact, particularly contributions not yet recognized by the field's most prominent awards.

GlobeNewsWire • Apr 21, 2026

Royalty Pharma Declares Second Quarter 2026 Dividend

NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share.

GlobeNewsWire • Apr 17, 2026